7525^ Background: Despite initial responses to reversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors,(erlotinib or gefitinib), all non-small cell lung cancer …

Background AR to reversible epidermal growth factor receptor (EGFR)-specific tyrosine
kinase inhibitors (TKIs) in EGFR mutant (mt) NSCLC is associated with an exon 20 EGFR …

Purpose: The EGFR tyrosine kinase inhibitors (TKIs), erlotinib and afatinib, have transformed
the treatment of advanced EGFR-mutant lung adenocarcinoma. However, almost all patients …

EGFR-mutant lung cancers responsive to reversible EGFR inhibitors (gefitinib/erlotinib)
develop acquired resistance, mediated by second-site EGFR T790M mutation in> 50% of …

Background The purpose of this study was to evaluate the efficacy of afatinib in EGFR-
mutant metastatic NSCLC patients with acquired resistance to erlotinib or gefitinib. Materials …

PURPOSE The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR
monoclonal antibody cetuximab was previously shown to overcome resistance to EGFR …

Somatic, activating mutations in EGFR identify a significant minority of patients with non–
small cell lung cancer (NSCLC). Although these mutations are associated with an …

Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Non‐small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor
(EGFR) mutation have benefited from treatment of reversible EGFR tyrosine kinase inhibitors …

Epidermal growth factor receptor (EGFR) mutations, especially EGFR-exon 19 deletions and
EGFR-L858R, are the most frequent actionable genomic events in lung adenocarcinomas …